TIDMPOLB
Poolbeg Pharma PLC
29 November 2022
Poolbeg Pharma plc
Influenza Artificial Intelligence model build completed
CytoReason analysis of human challenge trial data on track to
deliver outputs in Q2 2023
29 November 2022 - Poolbeg Pharma (AIM: POLB, OTCQB: POLBF,
'Poolbeg' or the 'Company'), a clinical stage infectious disease
pharmaceutical company with a unique capital light clinical model,
announces that, further to its announcement in March 2022 , the
construction of the computational artificial intelligence (AI)
influenza disease model has been completed by CytoReason Limited
('CytoReason'), indicating that it is on track to deliver outputs
in Q2 2023.
The model aims to unlock clinically meaningful insights into
influenza infection and recovery through the analysis of Poolbeg's
unique human challenge trial data. CytoReason has now built a
tailored AI model using Poolbeg's data which will allow the team to
identify novel influenza drug targets for Poolbeg.
CytoReason's technologies are externally validated through its
commercial partnerships with five of the world's top ten global
pharma companies accessing its world-leading AI models, including
Pfizer, Roche, and Sanofi. CytoReason's application of Poolbeg's
unique human challenge trial data to build and train its first AI
model in infectious diseases further testifies to the value of this
data.
CytoReason's world leading algorithms and experts will enable
the Poolbeg team to identify the most promising drug targets to
treat disease. The Company plans to source drugs with existing
Phase I safety data that, in line with the Poolbeg business model,
can immediately continue clinical development to rapidly generate
early human proof of concept data for influenza, with the ultimate
aim of monetising the asset through partnerships and licensing
deals with pharma and biotech .
Jeremy Skillington, PhD, CEO of Poolbeg Pharma, said:
"CytoReason builds world-class AI disease models and we look
forward with great anticipation to the outputs from their analysis
of our unique repository of clinical samples and associated data
from influenza human challenge trials. Indeed this is the first
time that AI is being used to analyse influenza human challenge
trial data which Poolbeg is proud to be part of."
"Completion of this first stage of development demonstrates yet
another milestone reached in the Company's stated R&D strategy
and brings us one step closer to realising the significant
opportunities that arise from this partnership. There is a growing
focus on AI discovered drug targets within the industry and we are
assessing interest in collaboration opportunities for our
AI-enabled novel targets which we expect in Q2 2023 from this
programme. "
David Harel, CEO of CytoReason, said:
"Now that our influenza disease model has been enriched by
Poolbeg's unparalleled data, we are excited to evaluate the novel
disease mechanisms on our platform. This will potentially identify
drug targets that can be used to develop treatments for influenza,
a significant global health threat, in a much shorter time-frame
and more cost effectively than with traditional reductionist
analysis and drug discovery techniques."
-Ends-
Enquiries
Poolbeg Pharma Plc
Jeremy Skillington, CEO
Ian O'Connell, CFO +44 (0) 207 183 1499
finnCap Ltd (Nominated Adviser & Joint
Broker)
Geoff Nash, Charlie Beeson, Nigel Birks,
Harriet Ward (ECM) +44 (0) 207 220 0500
Singer Capital Markets (Joint Broker)
Phil Davies, Sam Butcher +44 (0) 207 496 3000
J&E Davy (Joint Broker)
Anthony Farrell, Niall Gilchrist +353 (0) 1 679 6363
Instinctif Partners +44 (0) 20 7457 2020
Melanie Toyne Sewell, Rozi Morris, Tim poolbeg@instinctif.com
Field, Adam Loudon
Further detail on Poolbeg's Artificial Intelligence
Programmes
Poolbeg Pharma has access to a unique private repository of
clinical samples and associated data from human challenge trials
via its relationship with hVIVO plc (formerly Open Orphan plc), a
resource which is anticipated to expand over the coming years. Data
from human challenge trials are unique in that they track a healthy
subject through disease to recovery in carefully controlled and
monitored isolation units, collecting samples throughout the course
of disease, and vitally collecting matched baseline and follow-up
samples before and after infection. This data is unique in the
depth of longitudinal virology, health, biomarker and symptom data
collected during the course of disease. These datasets provide
clinical insights into disease that guides Poolbeg Pharma's product
acquisitions and clinical development.
CytoReason's machine learning algorithm works by combing through
enormous repositories of clinical data to build models of human
disease, which can then be used by biotech and pharmaceutical
partners to identify novel targets, prioritise mono/combination
therapies, find biomarkers, and understand which patients will
benefit most from those new treatments. CytoReason will be
analysing blood transcriptomics, proteomics, DNA sequences and
viral loads and disease signs and symptoms from the human challenge
trials. The aim is for CytoReason to prioritise new drug targets
quickly and cost effectively, in a manner consistent with Poolbeg's
business model.
The Company is currently progressing two AI Programmes, the
first in RSV in partnership with OneThree Biotech , and the second
in influenza in partnership with CytoReason . Poolbeg believe that
this is the first time that AI analysis has been undertaken on RSV
and influenza human challenge trial data and samples to identify
new drug targets and treatments. The unique nature of human
challenge trials to produce disease progression data with high
precision is revolutionising the insights into human disease.
About Influenza
Influenza is a viral pathogen that infects approximately
one-eighth of the world's population each year, an estimated 1
billion people infected globally, attacking the respiratory system
leading to between 5 and 10 million hospitalisations and as many as
500,000 influenza related deaths. Survivors of influenza can suffer
organ damage, leading to chronic and life-changing injuries. Health
organisations have warned that the upcoming influenza season could
be especially severe, as a consequence of low immunity to the virus
due to the pandemic causing a break in exposure.
About Poolbeg Pharma
Poolbeg Pharma is a clinical stage infectious disease
pharmaceutical company, with a unique capital light clinical model
which aims to develop multiple products faster and more cost
effectively than the conventional biotech model. The Company,
headquartered in London, is led by a team with a track record of
creation and delivery of shareholder value and aspires to become a
"one-stop shop" for pharma and biotech seeking mid-stage products
to license or acquire.
The Company is targeting the growing infectious disease market.
In the wake of the COVID-19 pandemic, infectious disease has become
one of the fastest growing pharma markets and is expected to exceed
$250bn by 2025.
With its initial assets from hVIVO plc (formerly named Open
Orphan plc), an industry leading infectious disease and human
challenge trials business, Poolbeg has access to knowledge,
experience, and clinical data from over 20 years of human challenge
trials. The Company is using these insights to acquire new assets
as well as reposition clinical stage products, reducing spend and
risk. Amongst its portfolio of exciting assets, Poolbeg has a small
molecule immunomodulator for severe influenza (POLB 001) which has
commenced its LPS human challenge trial with initial results
expected by year end 2022; a first-in-class, intranasally
administered RNA-based immunotherapy for respiratory virus
infections (POLB 002); and a vaccine candidate for Melioidosis
(POLB 003). The Company is also developing an oral vaccine delivery
platform and is progressing two artificial intelligence (AI)
programmes to accelerate the power of its human challenge model
data and biobank, with results from the first programme expected by
year end 2022.
For more information, please go to www.poolbegpharma.com or
follow us on Twitter and LinkedIn @PoolbegPharma.
About CytoReason
CytoReason is a leading technology company developing
computational disease models. The company collects proprietary data
from pharmaceutical companies and uses it to simulate human
diseases - tissue by tissue and cell by cell. With CytoReason's
massive database and AI-led platform, pharma and biotech companies
can identify new opportunities, shorten trial phases, reduce
development costs, and increase the likelihood of drug approval. To
date, five of the world's top ten pharma companies use CytoReason's
technology. For more information, visit www.cytoreason.com or
follow us on LinkedIn or Twitter.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRABKFBKBBDBDDB
(END) Dow Jones Newswires
November 29, 2022 02:00 ET (07:00 GMT)
Poolbeg Pharma (LSE:POLB)
Historical Stock Chart
From Jun 2024 to Jul 2024
Poolbeg Pharma (LSE:POLB)
Historical Stock Chart
From Jul 2023 to Jul 2024